Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.

Rofe, O; Bar-Sela, G; Keidar, Z; Sezin, T; Sadik, C D; Bergman, R

Rofe, O; Bar-Sela, G; Keidar, Z; Sezin, T; Sadik, C D; Bergman, R.

Afiliación

Rofe O; Department of Dermatology, Rambam Health Care Campus, Technion, Institute of Technology, Haifa, Israel.
Bar-Sela G; Department of Oncology, Rambam Health Care Campus, Technion, Institute of Technology, Haifa, Israel.
Keidar Z; Department of Nuclear Medicine, Rambam Health Care Campus, Technion, Institute of Technology, Haifa, Israel.
Sezin T; Department of Dermatology, Allergy and Venereology, University of Lubeck, Lubeck, Germany.
Sadik CD; Department of Dermatology, Allergy and Venereology, University of Lubeck, Lubeck, Germany.
Bergman R; Department of Dermatology, Rambam Health Care Campus, Technion, Institute of Technology, Haifa, Israel.

Clin Exp Dermatol ; 42(3): 309-312, 2017 Apr.

Article en En | MEDLINE | ID: mdl-28211077

Asunto(s)

Anticuerpos Monoclonales Humanizados/efectos adversos; Antineoplásicos/efectos adversos; Melanoma/tratamiento farmacológico; Penfigoide Ampolloso/inducido químicamente; Neoplasias Cutáneas/tratamiento farmacológico; Femenino; Humanos; Melanoma/secundario; Persona de Mediana Edad; Penfigoide Ampolloso/tratamiento farmacológico; Penfigoide Ampolloso/inmunología; Neoplasias Cutáneas/secundario

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Penfigoide Ampolloso / Anticuerpos Monoclonales Humanizados / Melanoma / Antineoplásicos Tipo de estudio: Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Clin Exp Dermatol Año: 2017 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google